Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 versus PREMASOL 6 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 versus PREMASOL 6 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% vs PREMASOL 6% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis, providing essential and non-essential nitrogen sources for anabolism in patients unable to tolerate oral or enteral nutrition.
Intravenous amino acid solution providing essential and non-essential amino acids for protein synthesis, nitrogen balance, and maintenance of lean body mass. Amino acids are actively transported into cells and incorporated into proteins; also serves as a caloric source.
Intravenous infusion of 250-500 mL/day (8.75-17.5 g amino acids) as a component of parenteral nutrition; rate up to 125 mL/hour; titrate based on metabolic response.
Intravenous infusion: 1 to 1.5 g/kg/day (amino acids) as part of total parenteral nutrition; typically 500 mL to 1000 mL per day, infused over 12-24 hours.
None Documented
None Documented
Terminal elimination half-life of individual amino acids ranges from 10 to 30 minutes for most, with glutamine and arginine slightly longer (30–45 min). No defined half-life for the mixture; clinically, steady-state achieved in 2–3 hours with continuous infusion.
Amino acids have rapid plasma clearance; elimination half-life varies from minutes to hours depending on individual amino acid; clinically, infused amino acids are cleared within 2-4 hours after infusion cessation.
Renal: 95% of infused amino acids are reabsorbed; excess amino acids are deaminated and urea is excreted renally. Fecal/Biliary: negligible (<1%).
Renal elimination of amino acids and metabolites; complete metabolism with nitrogen excretion as urea in urine; minimal biliary/fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution